Molecular epidemiology biomarkers - Sample collection and processing considerations
Molecular epidemiology biomarkers - Sample collection and processing considerations
复制标题
DOI：
10.1016/j.taap.2004.10.024
复制
发表时间：
2005-08-07
影响因子：
3.8
通讯作者：
Bastaki, M
中科院分区：
文献类型：
--
作者：
Holland, NT;Pfleger, L;Bastaki, M
生物标记物研究需要处理和存储大量的生物样本，目的是获得大量信息，并将未来的研究成本降至最低。有效的研究设计包括对原始样本的处理，如冷冻保存、DNA分离和为暴露评估准备样本。使用标准的二维和纳米条形码以及定制的电子数据库，可确保有效管理大样本收集和跟踪数据分析结果。标准的操作程序和质量控制程序有助于保护样品质量，并确保生物标志物数据的有效性。关于人体样本的研究，制定了具体的州、联邦和国际法规，管理领域包括人类样本的保管、处理安全和运输。在样本采集和结果保密之前，必须获得研究对象的适当知情同意。最后，使用了三个不同规模的生物库(欧洲癌症研究、国家癌症研究所和加州大学伯克利分校公共卫生学院生物库)的例子来说明研究人员面临的挑战和克服这些挑战的方法。许多公司正在开发新的软件和生物库技术，这将有助于将生物银行提高到21世纪分子流行病学所需的新水平。(C)2005 Elsevier Inc.保留所有权利。
Biomarker studies require processing and storage of numerous biological samples with the goals of obtaining a large amount of information and minimizing future research costs. An efficient study design includes provisions for processing of the original samples, such as cryopreservation, DNA isolation, and preparation of specimens for exposure assessment. Use of standard, two-dimensional and nanobarcodes and customized electronic databases assure efficient management of large sample collections and tracking results of data analyses. Standard operating procedures and quality control plans help to protect sample quality and to assure validity of the biomarker data. Specific state, federal and international regulations are in place regarding research with human samples, governing areas including custody, safety of handling, and transport of human samples. Appropriate informed consent must be obtained from the study subjects prior to sample collection and confidentiality of results maintained. Finally, examples of three biorepositories of different scale (European Cancer Study, National Cancer Institute and School of Public Health Biorepository, University of California, Berkeley) are used to illustrate challenges faced by investigators and the ways to overcome them. New software and biorepository technologies are being developed by many companies that will help to bring biological banking to a new level required by molecular epidemiology of the 21st century. (c) 2005 Elsevier Inc. All rights reserved.